Abstract
Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Current Pharmaceutical Design
Title: IgE, Allergic Diseases, and Omalizumab
Volume: 12 Issue: 30
Author(s): L. M. DuBuske
Affiliation:
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Abstract: Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Export Options
About this article
Cite this article as:
DuBuske L. M., IgE, Allergic Diseases, and Omalizumab, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559641
DOI https://dx.doi.org/10.2174/138161206778559641 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) Advancement in Microbial Cheminformatics
Current Topics in Medicinal Chemistry Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy Modifications of the Immune Responsiveness in Patients with Autoimmune Thyroiditis: Evidence for a Systemic Immune Alteration
Current Pharmaceutical Design Anti-inflammatory and Antitumor Properties of Eriobotrya Japonica Lindl: Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Immunopathogenesis of Severe Asthma
Current Pharmaceutical Design Chemokines and Their Receptors in Chronic Pulmonary Disease
Current Drug Targets - Inflammation & Allergy Low Rank Representation and Its Application in Bioinformatics
Current Bioinformatics Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Suramin Attenuated Inflammation and Reversed Skin Tissue Damage in Experimentally Induced Atopic Dermatitis in Mice
Inflammation & Allergy - Drug Targets (Discontinued) MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design A High Accumulation of Hair Minerals in Mongolian People: 2nd Report; Influence of Manganese, Iron, Lead, Cadmium and Aluminum to Oxidative Stress, Parkinsonism and Arthritis
Current Aging Science Natural Resins and Bioactive Natural Products thereof as Potential Anitimicrobial Agents
Current Pharmaceutical Design Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets New Strategies for Allergen Immunotherapy
Recent Patents on Inflammation & Allergy Drug Discovery New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry